NICE Endorses Rozanolixizumab for Myasthenia Gravis Treatment

Rozanolixizumab myasthenia gravis treatment has been recommended by the National Institute for Health and Care Excellence (NICE) as an add-on to standard care for adults with generalised myasthenia gravis (gMG) who are positive for anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibodies.

The recommendation is limited to patients with Myasthenia Gravis Foundation of America (MGFA) class 2 to 4a disease that remains uncontrolled despite two or more prior treatments (excluding acetylcholinesterase inhibitors). Rozanolixizumab myasthenia gravis therapy is positioned for those who would otherwise receive intravenous immunoglobulin (IVIg) or plasma exchange (PLEX), or who have discontinued these due to side effects or lack of efficacy. The treatment will be available on the NHS in England subject to a confidential commercial arrangement.

Strong Clinical Evidence from Key Trials

The phase 3 MycarinG study showed that rozanolixizumab plus standard care delivered a statistically significant reduction in MG Activities of Daily Living (MG-ADL) score at day 43 compared with standard care alone, both in the overall population and the refractory subgroup. Higher response rates, defined as at least a 2-point MG-ADL improvement, were observed with rozanolixizumab. Open-label extension data further confirmed sustained reductions in MG-ADL scores and clinically meaningful rates of minimal symptom expression across multiple treatment cycles.

Superiority Over Current Options

Indirect treatment comparisons indicated that rozanolixizumab is more effective than IVIg in achieving MG-ADL response. These benefits translate into improved daily functioning and reduced symptom burden for patients facing frequent exacerbations, myasthenic crises, and considerable physical, emotional, and financial strain.

Economic Model Supports NHS Funding

NICE’s evaluation used a cohort state-transition model over a 52.5-year horizon to assess long-term value. The committee concluded that the most plausible incremental cost-effectiveness ratios fell within an acceptable range for a rare condition, taking into account uncaptured benefits such as homecare administration and reduced hospital burden. This decision paves the way for routine commissioning within 90 days of final guidance publication.

Source: NICE issues final draft guidance recommending rozanolixizumab

Precedent for FcRn Inhibitors in Rare Diseases

The recommendation sets an important precedent for neonatal fragment crystallisable receptor (FcRn) inhibitors in refractory gMG. It demonstrates that innovative immunomodulatory therapies can secure routine NHS funding even without head-to-head trials against IVIg and PLEX, provided robust indirect comparisons and real-world evidence are presented.